Browsing tag:


Gemifloxacin Mesylate is a reliable and effectual antibiotic. Known as Factive, which is marketed by LG Life Sciences, the patent for gemifloxacin mesylate is due to expire on June 15, 2015. This once daily, 320 milligram tablet is the only FDA approved drug indicated for the treatment of acute bacterial exacerbation of chronic bronchitis caused[…]

Read More

Gatifloxacin is a quinolone antibiotic also known as Tequin. While Tequin, which is marketed by Bristol- Myers Squibb is no longer sold as a tablet in the U.S., it is still sold in other countries in tablet form, like China. In the United States gatifloxacin is sold as an opthalmic solution, also known as Zymar,[…]

Read More

LGM Pharma Acquires CDMO

On July 27, 2020, LGM Pharma announced its acquisition of the formulation development and drug product contract manufacturing business of Nexgen Pharma, Inc. As a result, you will notice our new logo and visuals throughout the website. We’re working on updates to reflect the exciting, expanded CDMO capabilities and services we now can offer you.

This website uses cookies. By using our site, you agree to our terms of service